Appointment of New Chief Financial Officer
Oxford, UK – 28 February 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, announces that Stuart Paynter will join Oxford BioMedica as Chief Financial Officer to succeed Tim Watts, who has decided to retire from full time executive roles. Stuart… Read More
Oxford BioMedica Notes Encouraging Results of the Investigator Led Phase I/II clinical trial of MVA-5T4 Immunotherapy (TroVax®) and Low Dose Cyclophosphamide in Patients with Advanced Colorectal Cancer
~ Both Cyclophosphamide and TroVax® independently shown to induce highly beneficial anti-tumour immune responses, resulting in significantly prolonged survival of advanced colorectal cancer patients Oxford, UK – 24 February 2017: Oxford BioMedica plc (LSE:Oxford Biomedica) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today notes the results from… Read More
Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting
Oxford, UK & London, UK– 5 December 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, today notes the findings reported by Novartis on their clinical trial (ELIANA) evaluating the efficacy and safety of CTL019, an investigational chimeric antigen receptor… Read More
Oxford BioMedica Announces a Strategic Alliance with Orchard Therapeutics
Oxford, UK & London, UK– 29 November 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, today announces it has entered into a strategic alliance with Orchard Therapeutics (“Orchard”), a biotechnology company dedicated to bringing transformative ex-vivo stem cell based… Read More
Oxford BioMedica Announces Publication of Pioneering RetinoStat® (Oxford Biomedica-201) Phase I Study Data in the Journal, Human Gene Therapy
— RetinoStat® met its primary endpoint, demonstrating favourable safety and tolerability profiles Oxford, UK – 10 October 2016: Oxford BioMedica plc (LSE:Oxford… Read More
Oxford BioMedica Result of General Meeting and Directors Dealing
London, UK – 29 September 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, announces, in accordance with Listing Rule 9.6.18, that all resolutions proposed at its General… Read More
Interim Results for the six months ended 30 June 2016
Oxford BioMedica plc Interim Results for the six months ended 30 June 2016 Oxford, UK – 13 September 2016: Oxford BioMedica plc (LSE: Oxford Biomedica), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy… Read More
Oxford BioMedica Announces MHRA GMP Manufacturing Approvals and Completion of Expansion Phase
– World-class centre for lentiviral gene therapy bioprocessing and process development approved and fully operational – Capital expenditure and expansion of Group’s facilities now… Read More
Oxford BioMedica to Present at the Jefferies 2016 Healthcare Conference, New York
Oxford, UK – 6 June 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces that Tim Watts, Chief Financial Officer, will be presenting at the Jefferies 2016… Read More
Establishment of a New Non-Exclusive LentiVector® Licence with MolMed
Oxford, UK – 7 June 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces that it has signed a new non-exclusive licence under Oxford BioMedica’s LentiVector… Read More
Oxford BioMedica and Green Cross LabCell form a Partnership to Develop Gene-modified NK Cell Therapeutics in cancer
Unique combination of Oxford BioMedica’s LentiVector® delivery platform and Green Cross LabCell’s NK cell platform to generate a pipeline of differentiated products in cancer… Read More